Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Transcode Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 8 | 6 | −2 |
| Shares | 14.4K | 3.88K | −10.6K (−73.1%) |
| Value | $155.0K | $26.4K | −$128.6K (−82.9%) |
New holders (1)
Institutions that held Transcode Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 2,964 | $20.2K | 0.00% |
Sold out (3)
Institutions that held Transcode Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| DRW Securities, LLC | 11,702 | $125.8K |
| Citigroup Inc | 1,586 | $17.0K |
| Federation des caisses Desjardins du Quebec | 975 | $10.5K |